Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results for mezigdomide (MeziKd), showing a 52% reduction in the risk of disease progression or death versus carfilzomib plus dexamethasone alone. At the American Society of Clinical Oncology (ASCO) Annual Meeting, the median progression-free survival rose to 18 months from 8.3 months. BMS said the deeper response translated into higher rates of complete response or no detectable trace of disease, with 80% responding in the mezigdomide arm versus 53% in the comparator. The company also disclosed that grade 3 or 4 treatment-related adverse events were more frequent with the mezigdomide regimen. BMS framed mezigdomide as a cereblon E3 ligase modulator positioned as a successor opportunity for its long-running multiple myeloma franchise, while noting overall survival data remain immature.